A team of researchers has unveiled a new method called SAMENT that can selectively label cells encountered by cancer cells as they spread through the body. The technique, described in a study published today, provides a detailed view of the cellular makeup within microenvironments that favor metastatic growth. The work was reported by Genetic Engineering News.
The approach identifies the specific cell types that support cancer metastasis, revealing an unexpected driver of immune suppression in bone metastasis. This finding challenges existing assumptions about how metastatic niches are established and maintained.
SAMENT works by tagging cells in the path of migrating cancer cells, creating a molecular map of the tissues that enable tumor spread. The research highlights that immune suppression in bone metastases is driven by a distinct subset of cells, not previously associated with this role.
The study represents a significant step forward in understanding the biology of metastasis, potentially opening new avenues for therapeutic intervention. However, the technique has only been validated in preclinical models, and its applicability to human cancers remains to be demonstrated.
While the findings are promising, experts caution that translating these insights into clinical treatments will require extensive further research. The unexpected cellular driver in bone metastasis must be confirmed in human tissue samples before it can be targeted therapeutically.